Two Year Longitudinal Evaluation of HRCT (Novartis PJMR005 2101)

Specimen Information

Status: Specimens are Available
Specimens for banking were collected at baseline and at various time points over a 2 year time frame. Longitudinal HRCT scans were evaluated in this study as well.

<table>
<thead>
<tr>
<th>Visit #</th>
<th>Time From Baseline</th>
<th>Specimens Collected</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>+0 Days</td>
<td>EDTA plasma, Urine</td>
</tr>
<tr>
<td>4</td>
<td>+3 Months</td>
<td>EDTA plasma, Urine</td>
</tr>
<tr>
<td>5</td>
<td>+1 Years</td>
<td>EDTA plasma, Urine</td>
</tr>
<tr>
<td>6</td>
<td>+2 Years</td>
<td>EDTA plasma, Urine</td>
</tr>
</tbody>
</table>

Study Design

Study Type? Observational
Randomized Study? No
Placebo Controlled? No
Length of Participation 2 Years
Number of Study Visits? 4

Additional Information

Phase? Not Applicable
Study Sponsor? Novartis
Study Drugs? N/A

Eligibility

Age 7 Years to 18 Years
Mutation(s) No Mutation Requirement
FEV1% Predicated 80 % or greater
PA Status Not Applicable
Other Subjects were required to be clinically stable at baseline.
Study Results

STUDY RESULTS NOT YET AVAILABLE